How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Seasonal Influenza Vaccines Market
- By Vaccine Type: Inactivated Influenza Vaccine (IIV), Live Attenuated Influenza Vaccine (LAIV), Recombinant Influenza Vaccine (RIV), Adjuvanted Influenza Vaccine
- By Age Group: Pediatric (6 months to 17 years), Adult (18 to 64 years), Geriatric (65 years and above)
- By End User: Hospitals, Clinics, Pharmacies, Public Health Centers, Home Care Settings
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Government Immunization Programs
- By Technology Platform: Egg-based Vaccine Production, Cell-based Vaccine Production, Recombinant DNA Technology
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Inactivated Influenza Vaccine (IIV) leads By Vaccine Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Seasonal Influenza Vaccines Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Vaccine Type 4
Age Group 3
End User 5
Distribution Channel 4
Technology Platform 3
Companies profiled
Sanofi Pasteur
GlaxoSmithKline (GSK)
Seqirus (a CSL company)
AstraZeneca
Pfizer
Bharat Biotech
Novartis (now part of GSK)
Mylan (now part of Viatris)
Baxter International
Sinovac Biotech
Shionogi & Co. Ltd.
Janssen Pharmaceuticals (Johnson & Johnson)
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Sanofi Pasteur
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →GlaxoSmithKline (GSK)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Seqirus (a CSL company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →AstraZeneca
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Pfizer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bharat Biotech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Novartis (now part of GSK)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Mylan (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Baxter International
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sinovac Biotech
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Shionogi & Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Janssen Pharmaceuticals (Johnson & Johnson)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Sanofi
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Serum Institute of India
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →
Global · 2025–2033
$3,483M by 2033 · 8.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Inactivated Influenza Vaccine (IIV)53.1
- Live Attenuated Influenza Vaccine (LAIV)7.7
- Recombinant Influenza Vaccine (RIV)18.7
- Adjuvanted Influenza Vaccine20.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$598.0M → $1,205M · 9.2%
Europe$416.8M → $735.4M · 7.4%
Asia Pacific$380.6M → $731.4M · 8.5%
Latin America$235.6M → $437.2M · 8.0%
Middle East and Africa$181.2M → $364.0M · 9.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.472026
8.472027
8.492028
8.512029
8.502030
8.522031
8.542032
8.552033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Sanofi Pasteur15.9
- GlaxoSmithKline (GSK)18.2
- Seqirus (a CSL company)8.6
- AstraZeneca13.6
- Pfizer8.5
- Bharat Biotech7.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Vaccine Type21.3%
Age Group20.7%
End User9.6%
Distribution Channel28.3%
Technology Platform20.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe21.2
- Asia Pacific21.1
- Latin America12.6
- Middle East and Africa10.5
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Sanofi Pasteur | 85 | 88 | 92 | 95 | 90 | 93 | 91 |
| GlaxoSmithKline (GSK) | 78 | 88 | 74 | 75 | 79 | 72 | 78 |
| Seqirus (a CSL company) | 67 | 85 | 62 | 62 | 74 | 69 | 70 |
| AstraZeneca | 81 | 67 | 75 | 81 | 78 | 79 | 77 |
| Pfizer | 64 | 62 | 73 | 53 | 63 | 60 | 63 |
| Bharat Biotech | 64 | 60 | 47 | 49 | 66 | 68 | 59 |
| Novartis (now part of GSK) | 51 | 62 | 45 | 47 | 55 | 65 | 54 |
| Mylan (now part of Viatris) | 40 | 59 | 57 | 45 | 48 | 38 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Seqirus (a CSL company)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Sanofi Pasteur | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| GlaxoSmithKline (GSK) | ◐ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Seqirus (a CSL company) | ✓ | ✓ | − | ◐ | ✓ | ✓ |
| AstraZeneca | ◐ | − | ◐ | ◐ | ✓ | ◐ |
| Pfizer | − | − | ✓ | ◐ | − | − |
| Bharat Biotech | − | ◐ | ◐ | − | ◐ | ◐ |
| Novartis (now part of GSK) | − | ◐ | − | − | − | − |
| Mylan (now part of Viatris) | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Sanofi Pasteur91
2GlaxoSmithKline (GSK)78
3AstraZeneca77
4Seqirus (a CSL company)70
5Pfizer63
6Bharat Biotech59
7Novartis (now part of GSK)54
8Mylan (now part of Viatris)48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Sanofi PasteurGlaxoSmithKline (GSK)
Challenger2
Strong scale, closing on the leaders.
Seqirus (a CSL company)AstraZeneca
Contender2
Focused players with pockets of strength.
PfizerBharat Biotech
Niche2
Specialists in a single segment or region.
Novartis (now part of GSK)Mylan (now part of Viatris)
Go-to-market strategy
Land Vaccine Type in North America, then scale across Seasonal Influenza Vaccines Market — a $211M beachhead inside a $3.36B market.
Beachhead (SOM)$211Mobtainable near-term
Serviceable (SAM)$1.38Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Inactivated Influenza Vaccine (IIV)
Best fit — highest urgency & budget in Vaccine Type.
Economic buyer80 fit
Live Attenuated Influenza Vaccine (LAIV)
Strong fit — clear ROI and a fast path to value.
End user65 fit
Recombinant Influenza Vaccine (RIV)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Vaccine Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Age Group & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel27%
Digital / self-serve23%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Vaccine Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Seasonal Influenza Vaccines Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified22%
Evaluation11%
Closed-won7%
$18.4KCAC
$84KLTV
4.5:1LTV : CAC
< 3 moCAC payback
Investment thesis
Seasonal Influenza Vaccines Market is a durable-growth opportunity — $8.32B by 2033, compounding at 9.5%.
TAM · 2025$4.03Btoday
TAM · 2033$8.32Bforecast
CAGR9.5%2027–2033
Cumulative$53.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.32BTotal addressable market
SAM$3.08BServiceable available market
SOM$673MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.5% CAGR
Demand compounds through 2033, outpacing GDP across Vaccine Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Vaccine Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.32BLarge & growingTAM by 2033 at 9.5% CAGR
$3.08BServiceable nowreachable with today’s model
$673MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.49BBear6.2% CAGR
$8.32BBase9.5% CAGR
$10.7BBull12.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Age Group optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Seasonal Influenza Vaccines Market — a $3.94B market by 2033. Plan: grow share from 7.9% to 14.0%.
Market size · 2033$3.94Btotal addressable
Market CAGR6.7%2027–2033
Target share14.0%from 7.9% today
Revenue ambition$552Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 14.0% | On track |
| Revenue | $284M | $552M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.0% | 40.3% | On track |
| Customer retention | 89.4% | 93.1% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Vaccine Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Age Group capability
A defensible second engine — invest in Age Group to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Vaccine Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Age Group
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $64M capacity & capability investment
- Greenlight bolt-on M&A in Age Group
- Authorise North America expansion plan
- Fund R&D program for Vaccine Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentOn track
Sales deck · value proposition
Win the Seasonal Influenza Vaccines Market conversation — a $813M market you can size, segment and defend in minutes.
Market size · 2033$813Mtotal opportunity
Growth8.2%CAGR to 2033
Addressable buyers1,153+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Vaccine Type
Goal Grow share in Vaccine Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 3 mopayback period
$76K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Sanofi PasteurGlaxoSmithKline (GSK)Seqirus (a CSL company)AstraZenecaPfizerBharat BiotechNovartis (now part of GSK)Mylan (now part of Viatris)+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Seasonal Influenza Vaccines Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Seasonal Influenza Vaccines Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →Oncology Drug Market
Market size, share, segmentation and regional forecast.
$13.2B by 2033 · 10.68% CAGR
View reportBiologic Therapeutics Drugs Market
Market size, share, segmentation and regional forecast.
$1.1B by 2033 · 4.44% CAGR
View reportSuperdisintegrants Market
Market size, share, segmentation and regional forecast.
$11.2B by 2033 · 6.23% CAGR
View reportBeta Blocker Market
Market size, share, segmentation and regional forecast.
$11.4B by 2033 · 4.09% CAGR
View reportHuman Vaccines Market
Market size, share, segmentation and regional forecast.
$4.5B by 2031 · 3.97% CAGR
View reportContraceptive Devices Market
Market size, share, segmentation and regional forecast.
$13.4B by 2033 · 3.39% CAGR
View reportNanoemulsions Market
Market size, share, segmentation and regional forecast.
$9.5B by 2033 · 9.37% CAGR
View reportOpioid Anesthetics Market
Market size, share, segmentation and regional forecast.
$12.0B by 2032 · 10.51% CAGR
View reportBiosimilar Monoclonal Antibodies Market
Market size, share, segmentation and regional forecast.
$4.9B by 2033 · 9.38% CAGR
View reportAnti-Retroviral Drugs Market
Market size, share, segmentation and regional forecast.
$8.1B by 2032 · 4.78% CAGR
View reportBone Morphogenetic Proteins Market
Market size, share, segmentation and regional forecast.
$12.5B by 2032 · 5.03% CAGR
View reportCellulite Treatment Market
Market size, share, segmentation and regional forecast.
$7.6B by 2033 · 10.27% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.